Matthew Maenner is surveillance team lead for the National Center on Birth Defects and Developmental Disabilities at the U.S. Centers for Disease Control and Prevention.
Matthew Maenner
Surveillance team lead
National Center on Birth Defects and Developmental Disabilities
From this contributor
Q&A with Matthew Maenner: Estimating autism prevalence quickly
A new method to track autism prevalence in 11 U.S. states is twice as fast as the old approach — and yields similar results.
Q&A with Matthew Maenner: Estimating autism prevalence quickly
By
Peter Hess
13 July 2021 | 6 min read
Explore more from The Transmitter
What leeches reveal about movement
Lidia Szczupak turned to the animals to explore how the nervous system coordinates movement.
What leeches reveal about movement
Lidia Szczupak turned to the animals to explore how the nervous system coordinates movement.
By
Claudia López Lloreda
27 August 2026 | 6 min read
By
Keerthana Iyer, Arish Mudra Rakshasa-Loots, Ana Silva, Violetta Zujovic
27 August 2026
6 min read
Redefining underrepresentation in global neuroscience
Shifting the focus of equity initiatives from identity categories to structural barriers can reveal overlooked challenges and increase support and participation worldwide.
Redefining underrepresentation in global neuroscience
Shifting the focus of equity initiatives from identity categories to structural barriers can reveal overlooked challenges and increase support and participation worldwide.
By
Keerthana Iyer, Arish Mudra Rakshasa-Loots, Ana Silva, Violetta Zujovic
27 August 2026 | 6 min read
Scientific talent is global. Access to the world’s scientific stage is not.
Neuroscience in Chile, and across Latin America, does not lack talent or ideas, but the systems that make science visible—prestigious journals, conferences and networks—increasingly price its researchers out.
Scientific talent is global. Access to the world’s scientific stage is not.
Neuroscience in Chile, and across Latin America, does not lack talent or ideas, but the systems that make science visible—prestigious journals, conferences and networks—increasingly price its researchers out.
By
Vicente Medel
27 August 2026 | 8 min read